NA-PHER2:曲妥珠单抗+帕妥珠单抗+哌柏西利+氟维司群新辅助治疗HER2阳性/ER阳性乳腺癌的探索性II期研究
NA-PHER2是一项在意大利7个中心开展的开放标签、多队列、探索性II期研究,评估曲妥珠单抗+帕妥珠单抗+哌柏西利+氟维司群新辅助治疗HER2阳性、ER阳性乳腺癌的疗效。主要终点为治疗2周和手术时Ki67表达变化及凋亡变化。
要点
- 临床客观缓解率97%(95%CI 83-100),病理完全缓解率27%(95%CI 12-46)。
- 最常见3级不良事件为中性粒细胞减少(29%),未记录4级或严重不良事件。
核心结论
- 哌柏西利+氟维司群+曲妥珠单抗+帕妥珠单抗联合方案对Ki67表达有显著影响,提示ER、HER2和RB1三重靶向可能成为HER2阳性/ER阳性乳腺癌的无化疗治疗策略。
研究设计与样本
- NA-PHER2为多队列、开放标签、探索性II期研究,在意大利7个中心开展。
- 纳入既往未经治疗、组织学确诊、单侧、浸润性、HER2阳性且ER阳性的乳腺癌患者,适合新辅助治疗。
- 治疗方案:每3周静脉曲妥珠单抗(负荷8 mg/kg后6 mg/kg)和帕妥珠单抗(首周期负荷840 mg后420 mg)共6周期,口服哌柏西利125 mg每日一次(4周周期中服21天),肌注氟维司群500 mg每4周一次共5周期。
- 共同主要终点为治疗2周和手术时(治疗16周后)Ki67表达相对基线的变化及基线至手术时凋亡变化。
- 35例纳入安全性分析,30例评估主要和次要终点。
主要发现
- 手术前临床客观缓解率97%(29/30;95%CI 83-100)。
- 手术时8/30例(27%;95%CI 12-46)达到乳腺和腋窝淋巴结病理完全缓解。
关键数值与推荐
- 临床客观缓解率:97%(29/30;95%CI 83-100)。
- 病理完全缓解率:27%(8/30;95%CI 12-46)。
- 最常见3级不良事件:中性粒细胞减少10例(29%)、腹泻5例(14%)、口腔炎/丙氨酸氨基转移酶升高/超敏反应各1例(3%)。
临床怎么用
- 对于HER2阳性/ER阳性乳腺癌患者,ER、HER2和RB1三重靶向的无化疗联合方案可能是一种有效的新辅助治疗策略。
- 该方案需进一步临床验证和分子特征分析,不仅限于激素受体阳性肿瘤,也应包括HER2未扩增肿瘤。
局限性
- 本研究为探索性II期研究,样本量较小(30例评估疗效)。
- 研究正在进行中,另有2个队列正在入组。
- 需进一步临床测试和分子特征分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the neoadjuvant setting, blockade of HER2 plus use of an aromatase inhibitor in patients with HER2-positive and oestrogen receptor (ER)-positive breast cancer leads to a pathological complete response in 21% of patients. Convergence of HER2 and ER signals on RB1 suggests that a combined pharmacological intervention directed to these targets could be synergistic. To test this approach, we combined palbociclib to block RB1, fulvestrant to block ER, and trastuzumab with pertuzumab to block HER2 in patients with HER2-positive, ER-positive breast cancer. METHODS: NA-PHER2 is a multicohort, open-label, exploratory, phase 2 study done at seven sites in Italy. Patients were eligible for the first cohort if they had previously untreated, histologically confirmed, unilateral, invasive, HER2-positive, ER-positive breast cancer and were suitable for neoadjuvant therapy. Patients were treated every 3 weeks with intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) and intravenous pertuzumab (840 mg loading dose in the first cycle and then at 420 mg) for six cycles plus oral palbociclib (125 mg once a day for 21 days in a 4-week cycle) and intramuscular fulvestrant (500 mg) every 4 weeks for five cycles. The coprimary endpoints were change from baseline in Ki67 expression at 2 weeks of treatment and at surgery (16 weeks after treatment) and changes in apoptosis from baseline to surgery. Secondary endpoints were clinical objective response (according to modified Response Evaluation Criteria in Solid Tumors) and pathological complete response. All patients who met eligibility criteria were assessed for the primary and secondary endpoints. All patients who received at least one cycle of therapy were assessed for safety. This trial is registered with ClinicalTrials.gov, number NCT02530424. The trial is ongoing and two further cohorts are being enrolled. FINDINGS: Between May 20, 2015, and Feb 8, 2016, we enrolled 36 patients, of whom one was deemed ineligible for the study and five were found to be HER2-negative on retrospective analysis. Thus, 35 patients were included in safety analyses and 30 were assessed for the primary and secondary endpoints. At baseline, geometric mean Ki67 expression was 31·9 (SD 15·7), versus 4·3 (15·0) at week 2 (n=25; p<0·0001) and 12·1 (20·0) at time of surgery (n=22; p=0·013). The geometric mean for apoptosis was 1·2 (SD 0·3) at baseline versus 0·4 (0·4; p=0·019) at surgery. A clinical objective response immediately before surgery was achieved by 29 (97%; 95% CI 83-100) of 30 patients. At surgery, eight (27%; 95% CI 12-46) patients had a pathological complete response in breast and axillary nodes. The most frequent grade 3 adverse events were neutropenia (ten [29%]), diarrhoea (five [14%]), and stomatitis, increased alanine aminotransferase, and hypersensitivity reactions (one [3%] of each event). No grade 4 or serious adverse events were recorded in the study and there were no deaths. INTERPRETATION: The combination of palbociclib, fulvestrant, trastuzumab, and pertuzumab had a significant effect on the expression of Ki67 at 2 weeks and at surgery. Triple targeting of ER, HER2, and RB1 in HER2-positive and ER-positive breast cancer could be an effective chemotherapy-free treatment strategy. Further clinical testing and additional molecular characterisation is necessary, not only in hormone receptor-positive tumours but also in tumours without HER2 amplification. FUNDING: Pfizer and Roche.
引用
- Gianni L, Bisagni G, Colleoni M, et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol. 2018. PMID: 29326029. doi:10.1016/S1470-2045(18)30001-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。